Helix Reader
Inside You

Q311 min at full depthPublished 23 Oct 2026

Hormone or neurotransmitter: which is a peptide?

The short answer

Either, and often both. A peptide is called a hormone when it travels through blood to far targets, and a neurotransmitter when it crosses the tiny gap between two nerve cells.

The short read

  1. The label depends on the route taken, not on the molecule.
  2. Oxytocin and vasopressin act as both.
  3. Peptide signals tend to be slower and longer lasting than small-molecule ones.

The two words describe delivery. A neurotransmitter is released at a synapse, a gap about 20 nanometres wide, and acts on the neighbour. A hormone enters the bloodstream and reaches distant organs. Many peptides do both jobs, and neuropeptides can drift beyond the synapse and affect a wider area of tissue.

The full explanation

People often sort messengers into two boxes. Peptides do not fit neatly in either.

Two routes

A neurotransmitter is released at a synapse, the junction where one nerve cell meets another. The gap is around 20 nanometres wide, so the message crosses almost at once and reaches one neighbour.

A hormone is released into the blood and travels. The target can be an organ at the other end of the body. Delivery takes longer, but one release can reach many tissues.

The same molecule on both routes

Oxytocin is released by nerve endings into the bloodstream from the pituitary gland, where it acts as a hormone. The same molecule is also released inside the brain, where it acts on nearby nerve cells. Vasopressin, somatostatin and cholecystokinin work the same way, depending on where they are released. A peptide can have several jobs because the route is not part of the molecule.

What peptide messengers do differently

Small-molecule transmitters such as dopamine or serotonin are made near the synapse and recycled quickly. Peptides are made in the cell body, packed in large vesicles, and shipped out along the nerve fibre. They are released when a nerve is firing hard. After release they can diffuse beyond the synapse, a form of signalling sometimes called volume transmission. They persist longer, and they usually act at lower concentrations.

The practical takeaway

When you read that a peptide acts on the brain, check which route is meant. Whether it is made in the brain or carried there from blood is a different question from whether it can cross the barrier that protects brain tissue, and the two are easy to confuse.

Jargon? Say it simply

Education only. Not medical advice, no dosing, no product recommendations. Read this first.

Keep going

Related questions

Q15Inside You

Cagrilintide Dosage Reference From Trials to Approval Status

No established cagrilintide dosage exists. The drug and the CagriSema combination had no approval in the sources checked on October 22, 2026, so there is no label dose, only supervised trial amounts.

  • CagriSema was filed with the FDA in December 2025, and no approval was found as of October 22, 2026.
  • Trial amounts were set by protocol under supervision, so they are not home instructions.
  • REDEFINE 1 reported 20.4 percent weight loss with CagriSema against 3.0 percent with placebo.

Cagrilintide is a long acting analog of amylin, a satiety hormone. It has no approved label, alone or inside the combination CagriSema, which Novo Nordisk submitted to the FDA in December 2025. The 2021 phase 2 trial and the REDEFINE trials tested supervised amounts and reported weight loss with more stomach side effects. Without a label, no one can give a safe self directed dose, and vendor tables have no validated source.

Q20Inside You

How Long Does It Take Oxytocin to Work and How Long Does It Last

Only the hospital drip has a firm answer: the uterus responds almost at once and the effect fades within an hour. Nasal sprays have no approved timing and no established dose.

  • The Pitocin label says the uterus responds almost immediately to a drip and the effect fades within an hour.
  • In one small nasal study, blood levels peaked within minutes while spinal fluid levels rose later.
  • A large 24 week trial in autism found no benefit over placebo, so there is no onset to time.

Timing depends on the route. For the approved hospital drip, the label gives a response in moments and a half life of a few minutes. For a muscle injection it gives minutes to start and hours of effect. Nasal sprays are not covered by that label, and a small study found blood and brain fluid levels move on different clocks. A large autism trial found no benefit, so no schedule exists for self use.

Q27Inside You

Why MOTS c Dosage Cannot Be Settled as Daily or Weekly

Nobody can say, because no human half-life or schedule comparison for MOTS c has been published. Mouse studies and early trials show biology, not a safe rhythm for people.

  • A frequency needs a half-life, and no human half-life for MOTS c has been published.
  • Mouse studies chose their own patterns and never compared daily with weekly.
  • Early human trials test whether it works, not which schedule is best.

Daily versus weekly sounds like a simple choice, but a schedule is derived from how long a molecule stays in the blood, and that has not been measured for MOTS c in people. Mouse papers treated animals repeatedly to see biology, and registered human trials use one fixed regimen to test benefit. Charts online fill the gap with borrowed or invented numbers, so none can be called an established dose.